A clear comparison
Semaglutide targets GLP-1 receptors, tirzepatide targets GIP and GLP-1 receptors, and retatrutide targets GIP, GLP-1 and glucagon receptors. More targets alone do not establish a better result.
The differences at a glance
Reference facts and current product information are separate below. On a small screen, swipe within the table; keyboard users can focus it and scroll with the arrow keys.
| Compare | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Reference · material class | GLP-1 receptor agonist | GIP / GLP-1 receptor agonist | Single peptide |
| Reference · identity and composition | Semaglutide; supplied form and specifications require matching documentation. | Tirzepatide; supplied form and specifications require matching documentation. | Retatrutide. Supplied form and exact specification require matching documentation. |
| Reference · research question | Metabolic research | Metabolic research | Weight management |
| Reference · evidence and limitations | Clinical comparisons describe specific interventions and populations, not the current research-material lot. | Two receptor targets distinguish this material from semaglutide. A mechanism does not by itself rank clinical outcomes or establish a current lot result. | Human trial evidence relates to specified investigational formulations and trial populations. This catalogue vial is not the trial formulation, and a larger package size does not mean a better outcome. |
| Reference · source papers | Aronne et al. (2025): tirzepatide compared with semaglutide | Aronne et al. (2025): tirzepatide compared with semaglutide | Jastreboff et al. (2023): phase 2 retatrutide obesity trial |
| Product · current sizes and prices | 5 mg · Price unavailable Out of stock | 10 mg · $64.99 In stock5 mg · $44.99 In stock | 5 mg · $69.99 In stock10 mg · $99.99 In stock20 mg · $179.99 In stock |
| Product · current stock | Out of stock | In stock | In stock |
| Product · supplied specification | Confirm form, identity and specification for the selected size. A field not reported remains unconfirmed. Product specifications | Confirm form, identity and specification for the selected size. A field not reported remains unconfirmed. Product specifications | Confirm form, identity and specification for the selected size. A field not reported remains unconfirmed. Product specifications |
| Product · matching lot records | No matching published record. Check Lab Results | No matching published record. Check Lab Results | No matching published record. Check Lab Results |
| Product · information and availability | Product information | View available options | View available options |
Product figures come from the current WooCommerce listing in the store currency. Package milligrams are nominal material amounts, not doses. No report for another sample or lot is substituted for a matching record.
One, two and three receptor targets
These names often appear together in weight-loss and weight-management searches. Their receptor profiles provide a simple starting map: semaglutide has one of the three target types in this comparison, tirzepatide has two, and retatrutide has three. Receptor count describes mechanism. It is not a clinical score and does not tell you that one product is appropriate for an individual.
Which studies are actually comparable?
A direct comparison gives participants different treatments within the same study design. The 2025 tirzepatide versus semaglutide obesity trial is such a study. The cited 2023 retatrutide study is a separate phase 2 trial. Comparing percentage changes across those separate papers without accounting for populations, follow-up, protocols and endpoints would produce a misleading league table.
Weight, visceral fat and metabolism
Body weight is one endpoint. Changes in glucose regulation, fat distribution and other metabolic measurements are different endpoints. Check which outcome the paper actually measured, how many people completed follow-up and which adverse events were reported. A short answer can explain the receptor difference, while the full paper is needed to understand the result.
What is available in this catalogue?
Tirzepatide and Retatrutide are listed in the Peptide Place research catalogue. Semaglutide is included here for comparison. The vial strengths shown in the catalogue describe nominal material amounts. The studies cited below evaluated specific trial formulations and do not establish equivalence with catalogue materials.
Common questions
Is retatrutide just another name for tirzepatide?
No. They are distinct compounds with different receptor profiles.
Can all three be ranked from these papers?
The cited studies do not provide a three-way head-to-head comparison. Separate trial results need context.
Original sources
These papers support the specific mechanisms or study models discussed above. They do not test the current Peptide Place catalogue batches.
- Jastreboff et al. (2023): phase 2 retatrutide obesity trial ↗
- Aronne et al. (2025): tirzepatide compared with semaglutide ↗
Continue exploring
Semaglutide 5 mg: current options and full overview →
Tirzepatide: current options and full overview →
Retatrutide vs Tirzepatide
The main mechanism distinction is three receptor targets versus two: retatrutide is associated with GIP, GLP-1 and glucagon receptor agonism; tirzepatide is associated with GIP and GLP-1 receptor agonism. That identifies a pharmacological difference. It does not, by itself, rank outcomes. Compare study populations, trial design, duration and measured endpoints before comparing results. Read the source evidence above rather than treating separate trial percentages as a direct head-to-head result.
Retatrutide vs Semaglutide
Semaglutide targets GLP-1 receptors; retatrutide is described through GIP, GLP-1 and glucagon receptor activity. The useful next question is which study and outcome you are comparing. Mechanism, clinical findings and a supplied product specification are different layers of information. For a pathway explanation, read GLP-1, GIP and glucagon receptors explained.
Tirzepatide vs Semaglutide
Tirzepatide is commonly described as a dual GIP/GLP-1 receptor agonist, while semaglutide is a GLP-1 receptor agonist. A fair evidence comparison keeps the population, comparator and endpoint visible. This page brings the related comparisons together so you can compare the same definitions and sources. A compound appearing here does not imply it is currently sold in the catalogue. Use the live Shop for availability.
Related reading: Retatrutide research profile

